A sickle cell disease “cure” is to be offered to NHS patients for the first time. The £1.65 million gene therapy called exa-cel, also known under the brand name Casgevy, uses a Nobel Prize ...

(Reuters) - The U.S. Food and Drug Administration (FDA) said on Thursday it had identified three cybersecurity risks associated with certain patient monitors from Contec and Epsimed and urged ...

January 30, 2025—Viz.ai announced an expanded partnership with Softek Illuminate, Inc. The company stated that the partnership seeks to enable health care providers to make timely decisions for ...

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with ...

(RTTNews) - Akero Therapeutics, Inc. (AKRO), Monday, announced encouraging preliminary topline Week-96 results from a phase IIb trial of its investigational drug Efruxifermin in patients with ...

Happiness Co Foundation — a charity dedicated to mental wellbeing and helping people live healthier lives — is introducing a series of events to add an extra twist to the traditional one-day ...

The ALS Association this summer will host the second edition of its ALS Nexus, a conference bringing together researchers, healthcare professionals, advocates, patients, and caregivers in a quest to ...

Since Annie’s Place was founded a decade ago, the nonprofit has allowed patients to keep nearly 15,000 medical appointments, according to the announcement A spokesperson for Parkland Health ...

More than three-quarters of patients with dementia were not aware of their diagnosis, according to results recently published in the Journal of General Internal Medicine. It’s not because the ...

Terminally ill patients given six months to live often survive for three years, official figures have revealed, fuelling fresh concern over assisted dying becoming legal. Patients who are given a ...

Qalsody (tofersen) halted disease progression and improved functional independence and mobility in people with amyotrophic lateral sclerosis (ALS) who received the treatment in a real-world setting, ...